These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26990259)

  • 1. Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Akamine Y; Habuchi T; Satoh S; Miura M
    Int J Urol; 2016 Jun; 23(6):484-90. PubMed ID: 26990259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients.
    Kagaya H; Niioka T; Saito M; Inoue T; Numakura K; Yamamoto R; Akamine Y; Habuchi T; Satoh S; Miura M
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29547545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
    Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
    J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients.
    David-Neto E; Agena F; Ramos F; Triboni AHK; Romano P; de Almeida Rezende Ebner P; Coelho V; Galante NZ; Lemos FBC
    Transplantation; 2017 Sep; 101(9):2133-2138. PubMed ID: 27798513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.
    Moes DJ; Press RR; den Hartigh J; van der Straaten T; de Fijter JW; Guchelaar HJ
    Clin Pharmacokinet; 2012 Jul; 51(7):467-80. PubMed ID: 22624503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
    Rostaing L; Christiaans MH; Kovarik JM; Pascual J
    Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.
    Renders L; Frisman M; Ufer M; Mosyagin I; Haenisch S; Ott U; Caliebe A; Dechant M; Braun F; Kunzendorf U; Cascorbi I
    Clin Pharmacol Ther; 2007 Feb; 81(2):228-34. PubMed ID: 17192769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.
    Alvarez-Elías AC; García-Roca P; Velásquez-Jones L; Valverde S; Varela-Fascinetto G; Medeiros M
    Transplant Proc; 2016 Mar; 48(2):631-4. PubMed ID: 27110018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
    Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
    Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.